Download PDF

Other users also viewed these articles

Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study Lidia Serrano Díaz; Carles Iniesta Navalón; Rosa Gómez Espín; Isabel Nicolás De Prado; Enrique Bernal Morell; Lorena Rentero Redondo;
Gastroenterol Hepatol. 2024;47:553-61
Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes Carles Iniesta-Navalón; Lorena Rentero-Redondo; Rosa Gómez-Espín; Manuel Ríos Saorín; Isabel Nicolás de Prado; Juan José Gascón-Cánovas;
Gastroenterol Hepatol. 2025;48:
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn¿s Disease and Ulcerative Colitis Francisco Rodríguez-Moranta; Federico Argüelles-Arias; Joaquín Hinojosa del Val; Marisa Iborra Colomino; M. Dolores Martín-Arranz; Luis Menchén Viso; Fernando Muñoz Núñez; Elena Ricart Gómez; José Germán Sánchez-Hernández; Teresa Valdés-Delgado; Jordi Guardiola Capón; Manuel Barreiro-de Acosta; Míriam Mañosa Ciria; Yamile Zabana Abdo; Ana Gutiérrez Casbas;
Gastroenterol Hepatol. 2024;47:522-52